Ann: DIRECTOR: PEB: Confirmation of Director Appointment

• Release Date: 05/04/16 12:05
• Summary: DIRECTOR: PEB: Confirmation of Director Appointment
• Price Sensitive: No
• Download Document  6.83KB

					PEB                                                                           
05/04/2016 12:05                                                              
DIRECTOR                                                                      
NOT PRICE SENSITIVE                                                           
REL: 1205 HRS Pacific Edge Limited                                            
                                                                              
DIRECTOR: PEB: Confirmation of Director Appointment                           
                                                                              
5 April 2016                                                                  
                                                                              
CONFIRMATION OF DIRECTOR APPOINTMENT                                          
                                                                              
Pacific Edge Limited (PEB:NZX) has today advised that David Levison's         
appointment as a Director has been confirmed, effective as at 2 April 2016.   
                                                                              
David is a US-based Director, with an indepth knowledge and experience in the 
US healthcare market. He is currently CEO and a Director of CardioDx, a       
specialist molecular diagnostic company similar to Pacific Edge.              
                                                                              
David is highly respected within the industry and has in market experience in 
building a successful medical diagnostics company in the US. His              
understanding of commercial molecular diagnostic products in the US           
healthcare market, will be of great value to Pacific Edge as it looks to      
expand in this region.                                                        
                                                                              
David will hold office until Pacific Edge's next Annual Shareholders' Meeting 
at which time he will offer himself for election by shareholders. The Board   
has determined that David Levison is an Independent Director, for the         
purposes of NZX Listing Rule 3.3.2.                                           
                                                                              
ENDS                                                                          
                                                                              
For more information contact:                                                 
                                                                              
David Darling                                                                 
Chief Executive Officer                                                       
Pacific Edge Ltd                                                              
P: +64 (3) 479 5800                                                           
                                                                              
OVERVIEW  www.pacificedge.co.nz   www.pacificedgedx.com                       
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer      
diagnostic company specialising in the discovery and commercialisation of     
diagnostic and prognostic tests for better detection and management of        
cancer. The company is developing and commercialising its range of Cxbladder  
bladder cancer tests globally through its wholly owned central laboratories   
in New Zealand and the USA. The company's products have been tested and       
validated in international multi-centre clinical studies. Pacific Edge has    
two proprietary, novel, accurate, molecular diagnostic products in-market     
providing actionable results, and better detection and management of          
urothelial cancer. Cxbladder Detect is available through the company's        
dedicated CLIA certified laboratories for customers in New Zealand, Australia 
and the USA. Cxbladder Triage is available in New Zealand and Australia.      
Cxbladder Monitor launched in New Zealand in December 2015 and is anticipated 
being available in the US in 2016.                                            
                                                                              
ABOUT Cxbladder Triage www.cxbladder.com                                      
Cxbladder Triage combines the power of the genomic biomarkers with additional 
phenotypic and clinical risk factors to accurately identify patients with     
haematuria who have a low probability of bladder cancer and may not require a 
more extensive urological evaluation. Cxbladder Triage is a tool for use by   
clinicians and physicians in primary evaluation of patients with hematuria    
and is intended to reduce the need for an expensive and invasive work-up in   
patients who have a low probability of having urothelial carcinoma.           
                                                                              
ABOUT Cxbladder Detect www.cxbladder.com                                      
Cxbladder Detect enables the non-invasive detection of bladder and other      
urinary tract cancers from a small volume of a patients' urine. Cxbladder     
Detect was launched in 2013 in the USA and is commercially available in New   
Zealand, Australia and the USA as a Laboratory Developed Test (LDT) from the  
company's CLIA certified laboratories. Cxbladder Detect provides physicians   
and clinicians with a quick, cost effective and accurate measure of the       
presence of the cancer as an effective adjunct to cystoscopy.                 
                                                                              
ABOUT Cxbladder Monitor  www.cxbladder.com                                    
Cxbladder Monitor, the third test in the Cxbladder portfolio for urologists,  
is a proprietary, non-invasive, molecular diagnostic test that combines       
genomic biomarkers measured from a small quantity of a patient's urine, with  
patient specific clinical factors to better monitor bladder cancer patients   
for recurrence. Bladder cancer has a recurrence rate of 50-80% and requires   
life-long surveillance. Cxbladder Monitor accurately identifies patients with 
a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows 
that they have a low probability of recurrent urothelial carcinoma. Cxbladder 
Monitor is designed to be used as the preferred adjunct test to cystoscopy in 
the management of patients for ongoing evaluation of recurrent bladder        
cancer.                                                                       
                                                                              
Refer to www.cxbladder.com for more information.                              
End CA:00280360 For:PEB    Type:DIRECTOR   Time:2016-04-05 12:05:30